Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 48: 2044-2045, 2002;
This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Thelen, M. H.M.
Right arrow Articles by Schutgens, R. B.H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thelen, M. H.M.
Right arrow Articles by Schutgens, R. B.H.
Related Collections
Right arrow Clinical Immunology
(Clinical Chemistry. 2002;48:2044-2045.)
© 2002 American Association for Clinical Chemistry, Inc.


Technical Briefs

Disclosure of Hidden Free Light Chains by Immunosubtraction

Marc H.M. Thelen1,2a, Jan van Bezu1, Astrid Kok1 and Ruud B.H. Schutgens1

1 Department of Clinical Chemistry, Vrije Universiteit Medical Centre, Amsterdam, Postbus 7057, 1007 MB Amsterdam, The Netherlands

2 Clinical Laboratory, St-Annaziekenhuis, Postbus 90, 5660 AB Geldrop, The Netherlands

aaddress correspondence to this author at: Clinical Laboratory, St-Annaziekenhuis, Postbus 90, 5660 AB Geldrop, The Netherlands; fax 31-40-2854945, e-mail m.thelen{at}st-anna.nl

The College of American Pathologists has recently defined and introduced guidelines for clinical and laboratory evaluation of patients with monoclonal gammopathies (1)(2)(3)(4). One of these guidelines states that all patients with multiple myeloma, Waldenström macroglobulinemia, amyloidosis, and related disorders should be assessed for the presence of urinary monoclonal free light chains by immunofixation electrophoresis (3). Because free light chains are associated with more aggressive disease, the clinical relevance lies with the quantities of free monoclonal light chains excreted and not with the intact immunoglobulins, which also may be present in the urine (2)(5). Here we demonstrate that in some cases the intact immunoglobulins comigrate with the free light chains in immunofixation electrophoresis, and we provide a method to disclose this interference.

In the diagnostic work-up of a patient suffering from multiple myeloma, we performed immunofixation electrophoresis on serum and concentrated urine using a immunofixation reagent set (Beckman) with anti-human immunoglobulin antibodies (Dako), according to the manufacturer’s protocol. Briefly, electrophoresis of 5 µL of 1:10 diluted serum (2 µL of serum plus 18 µL of buffer) and 5 µL of 50-fold concentrated urine was followed by immunofixation with 80 µL of antiserum. Unprecipitated proteins were washed away before staining of the precipitated complexes with Amido black.

Immunofixation electrophoresis of our patient’s urine revealed the same monoclonal pattern as was found in the patient’s serum; an IgG heavy chain with the same mobility as the {kappa} light chain (Fig. 1A , lanes 2 and 3). However, there was an unexpected discrepancy between the IgG heavy chain and the {kappa} light chain signal in favor of the latter.



View larger version (31K):
[in this window]
[in a new window]
 
Figure 1. Immunofixation electrophoresis on agarose gels of concentrated urines of three different patients.

(A), the index patient. Lanes contain urine prepared with different incubations and/or preincubations. Lane 1, fixative; lane 2, incubation with anti-IgG serum; lane 3, incubation with anti-{kappa} light chain serum; lane 4, incubation with anti-{lambda} light chain serum; lane 5, preincubation with anti-IgG antiserum before electrophoresis and incubation with anti-IgG serum after electrophoresis; lane 6, preincubation with anti-IgG antiserum before electrophoresis and incubation with anti-{kappa} after electrophoresis. (B), control patient. Lane 1, incubation with anti-IgG serum; lane 2, incubation with anti-{kappa} light chain serum; lane 3, preincubation with anti-IgG antiserum before electrophoresis and incubation with anti-IgG serum after electrophoresis; lane 4, preincubation with anti-IgG antiserum before electrophoresis and incubation with anti-{kappa} after electrophoresis; lane 5, preincubation with anti-IgA antiserum before electrophoresis and incubation with anti-IgG serum after electrophoresis; lane 6, preincubation with anti-IgA antiserum before electrophoresis and incubation with anti-{kappa} after electrophoresis. (C), a third patient. Lane 1, incubation with anti-IgG serum; lane 2, incubation with anti-{lambda} light chain serum; lane 3, preincubation with anti-IgG antiserum before electrophoresis and incubation with anti-IgG serum after electrophoresis; lane 4, preincubation with anti-IgG antiserum before electrophoresis and incubation with anti-{lambda} after electrophoresis; lane 5, preincubation with anti-IgA antiserum before electrophoresis and incubation with anti-IgG serum after electrophoresis; lane 6, preincubation with anti-IgA antiserum before electrophoresis and incubation with anti-{lambda} after electrophoresis.

To explore whether part of the light chain excess might be explained by the presence of free light chains, we used an immunosubtraction technique. We preincubated 10 µL of the concentrated urine with 20 µL of anti-IgG serum for 30 min at 37 °C and centrifuged the mixture (15 min at 12 000g) before applying 5 µL of the supernatant to the gel. The anti-IgG signal was not seen in the subsequent immunofixation. The anti-{kappa} signal, however, was only partly affected by the immunosubtraction, indicating that free {kappa} light chains indeed were responsible for part of the single monoclonal band in the electrophoretic pattern (Fig. 1AUp , lanes 5 and 6). Fig. 1BUp shows immunofixation of the urine of a control patient, with free light chains and intact immunoglobulins migrating at different positions on the gel, demonstrating that heavy chain immunosubtraction affects only the intact immunoglobulins and not the free light chain signals. Preincubation with anti-IgA did not affect the anti-{kappa} signal. Using this technique, we also identified more patients with a similar comigration phenomenon (Fig. 1CUp ).

Our results demonstrate that in immunofixation electrophoresis, free light chains indeed can be obscured by comigrating intact immunoglobulins. The presented immunosubtraction method provides a means to disclose this problem. Although the use of antibodies that specifically recognize only free light chains theoretically also can reveal such problems, reported problems with the sensitivities and specificities of such antibodies make results unpredictable and unsuitable for diagnostic use (1). The method we describe here combines the specificity of immunosubtraction with the sensitivity of immunofixation, making it an attractive addition to the arsenal of laboratory tests for gammopathies in cases where there is some doubt about the stoichiometry of immunoglobulin heavy and light chains.


References

  1. Kyle RA. Sequence of testing for monoclonal gammopathies [Review]. Arch Pathol Lab Med 1999;123:114-118.[Web of Science][Medline] [Order article via Infotrieve]
  2. Keren DF. Procedures for the evaluation of monoclonal immunoglobulins [Review]. Arch Pathol Lab Med 1999;123:126-132.[Web of Science][Medline] [Order article via Infotrieve]
  3. Keren DF, Alexanian R, Goeken JA, Gorevic PD, Kyle RA, Tomar RH. Guidelines for clinical and laboratory evaluation patients with monoclonal gammopathies. Arch Pathol Lab Med 1999;123:106-107.[Web of Science][Medline] [Order article via Infotrieve]
  4. Goeken JA, Keren DF. Introduction to the report of the consensus conference on monoclonal gammopathies [Review]. Arch Pathol Lab Med 1999;123:104-105.[Web of Science][Medline] [Order article via Infotrieve]
  5. Levinson SS, Keren DF. Free light chains of immunoglobulins: clinical laboratory analysis [Review]. Clin Chem 1994;40:1869-1878.[Abstract/Free Full Text]




This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Thelen, M. H.M.
Right arrow Articles by Schutgens, R. B.H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thelen, M. H.M.
Right arrow Articles by Schutgens, R. B.H.
Related Collections
Right arrow Clinical Immunology


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS